

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	45	39.8	113.0	(82.4-151.3)	Male	21	20.5	102.3	(63.3-156.4)
Female	15	16.7	89.8	(50.2-148.1)	Female	21	18.6	112.9	(69.8-172.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	7.8	64.1	(20.7-149.6)	Male	8	5.5	144.7	(62.3-285.1)
Female	2	7.4	nc	(nc-nc)	Female	6	5.2	114.9	(42.0-250.1)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)	Male	17	20.3	83.8	(48.8-134.3)
Female	180	169.8	106.0	(91.1-122.7)	Female	27	20.9	129.2	(85.1-188.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	8	8.2	98.1	(42.3-193.4)	Male	22	14.9	147.7	(92.5-223.7)
Colon / Rectum					Female	12	8.3	144.3	(74.5-252.1)
Male	65	61.3	106.0	(81.8-135.1)	Ovary				
Female	76	68.9	110.4	(87.0-138.2)	Female	19	17.5	108.3	(65.2-169.2)
Esophagus					Pancreas				
Male	10	9.5	105.1	(50.3-193.2)	Male	18	11.4	158.5	(93.9-250.5)
Female	5	3.4	148.8	(47.9-347.1)	Female	13	14.3	91.1	(48.4-155.7)
Hodgkin Lymphoma					Prostate				
Male	1	3.7	nc	(nc-nc)	Male	172	159.2	108.0	(92.5-125.5)
Female	5	3.5	144.0	(46.4-336.1)	Stomach				
Kidney & Renal Pelvis					Male	10	10.5	95.6	(45.8-175.9)
Male	24	15.7	153.0	(98.0-227.7)	Female	11	7.3	149.7	(74.6-267.8)
Female	8	11.7	68.2	(29.4-134.5)	Testis				
Larynx					Male	6	6.9	87.3	(31.9-189.9)
Male	9	7.0	128.0	(58.4-243.0)					

Female	2	2.1	nc	(nc-nc)
Leukemia				
Male	16	12.4	129.4	(73.9-210.1)
Female	18	11.6	154.8	(91.7-244.7)
Liver and Intrahepatic Bile Ducts				
Male	4	7.3	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)
Lung and Bronchus				
Male	101	77.5	130.3	(106.2-158.4)
Female	92	75.9	121.1	(97.7-148.6)

Thyroid

Male	5	4.1	123.4	(39.8-288.0)
Female	3	14.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	34	33.1	102.8	(71.2-143.6)
--------	----	------	-------	--------------

All Sites / Types

Male	592	531.6	111.4	(102.6-120.7)
Female	620	563.7	110.0	(101.5-119.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

269 Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	7.7	117.4	(53.6-222.8)	Male	2	4.2	nc	(nc-nc)
Female	6	2.7	222.3	(81.2-483.8)	Female	3	3.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.6	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
Female	28	31.1	89.9	(59.8-130.0)	Female	2	3.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Male	3	3.3	nc	(nc-nc)	Ovary	Male	3	1.5	nc	(nc-nc)
	Female	2	1.5	nc	(nc-nc)		Female	3	1.5	nc	(nc-nc)
	Male	24	12.0	199.8	(128.0-297.3)		Female	4	3.1	nc	(nc-nc)
Esophagus	Female	9	10.7	84.2	(38.4-159.8)	Pancreas	Male	4	2.3	nc	(nc-nc)
	Male	8	2.0	405.0	(174.4-798.0)		Female	2	2.2	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)		Male	38	33.4	113.9	(80.6-156.4)
Hodgkin Lymphoma	Male	1	0.7	nc	(nc-nc)	Prostate	Female	2	2.2	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)		Male	38	33.4	113.9	(80.6-156.4)
	Male	4	3.3	nc	(nc-nc)		Female	3	1.1	nc	(nc-nc)
Kidney & Renal Pelvis	Female	6	2.0	293.8	(107.3-639.6)	Stomach	Male	1	2.0	nc	(nc-nc)
	Male	4	3.3	nc	(nc-nc)		Female	3	1.1	nc	(nc-nc)
	Female	6	2.0	293.8	(107.3-639.6)		Male	2	1.2	nc	(nc-nc)
Larynx	Male	4	1.5	nc	(nc-nc)	Testis	Female	3	1.1	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)		Male	2	1.2	nc	(nc-nc)
	Male	4	1.5	nc	(nc-nc)		Female	3	1.1	nc	(nc-nc)
Leukemia	Female	2	1.9	nc	(nc-nc)	Thyroid	Male	1	0.8	nc	(nc-nc)
	Male	2	2.4	nc	(nc-nc)		Female	0	2.6	nc	(nc-nc)
	Female	2	1.9	nc	(nc-nc)		Male	1	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	2	2.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	0	2.6	nc	(nc-nc)
	Female	2	1.9	nc	(nc-nc)		Male	1	0.8	nc	(nc-nc)
	Male	2	2.4	nc	(nc-nc)		Female	0	2.6	nc	(nc-nc)
Lung and Bronchus	Female	0	0.5	nc	(nc-nc)	All Sites / Types	Female	7	6.2	112.5	(45.1-231.8)
	Male	21	15.4	136.2	(84.3-208.2)		Male	141	107.5	131.1	(110.4-154.7)
	Female	21	13.0	161.6	(100.0-247.0)		Female	107	97.3	110.0	(90.2-133.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

270
Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Colon / Rectum					Female	1	0.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	Ovary				
Female	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	7	6.1	115.2	(46.2-237.4)
Female	0	0.1	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	0	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)					

Larynx	Female	0	0.2	nc	(nc-nc)	Testis	Female	0	0.1	nc	(nc-nc)
	Male	1	0.3	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
Leukemia	Female	0	0.0	nc	(nc-nc)	Thyroid					
	Male	0	0.4	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.3	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	4	2.9	nc	(nc-nc)		Male	17	19.1	89.1	(51.9-142.6)
	Female	2	1.6	nc	(nc-nc)		Female	9	11.2	80.1	(36.5-152.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

271
Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	26	22.6	114.8	(75.0-168.3)	Male	25	11.4	218.7	(141.5-322.8)
Female	13	7.9	163.7	(87.1-279.9)	Female	19	8.9	213.5	(128.5-333.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	4.3	nc	(nc-nc)	Male	7	3.2	220.4	(88.3-454.1)
Female	7	3.6	193.1	(77.4-397.9)	Female	1	2.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	0	0.7	nc	(nc-nc)
Female	95	86.7	109.5	(88.6-133.9)
Cervix Uteri				
Female	4	4.0	nc	(nc-nc)
Colon / Rectum				
Male	33	34.9	94.5	(65.0-132.7)
Female	38	32.2	118.1	(83.6-162.1)
Esophagus				
Male	4	5.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	9	9.1	99.2	(45.3-188.4)
Female	3	5.8	nc	(nc-nc)
Larynx				
Male	4	4.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Leukemia				
Male	12	7.0	172.1	(88.8-300.6)
Female	12	5.6	216.1	(111.5-377.5)
Liver and Intrahepatic Bile Ducts				
Male	0	4.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	33	44.5	74.2	(51.0-104.2)
Female	29	37.1	78.2	(52.4-112.3)

Male	14	11.3	123.8	(67.6-207.7)
Female	5	10.0	50.2	(16.2-117.1)
Oral Cavity & Pharynx				
Male	5	8.7	57.3	(18.5-133.8)
Female	5	4.1	122.6	(39.5-286.1)
Ovary				
Female	13	8.7	148.8	(79.1-254.4)
Pancreas				
Male	6	6.5	92.1	(33.6-200.6)
Female	9	6.7	135.2	(61.7-256.6)
Prostate				
Male	116	92.2	125.9	(104.0-151.0)
Stomach				
Male	2	5.9	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)
Testis				
Male	3	2.8	nc	(nc-nc)
Thyroid				
Male	3	2.1	nc	(nc-nc)
Female	6	6.7	89.2	(32.6-194.1)
Uteri Corpus and Uterus, NOS				
Female	9	16.9	53.1	(24.2-100.8)
All Sites / Types				
Male	323	302.5	106.8	(95.4-119.1)
Female	296	276.0	107.2	(95.4-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

272
Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	45	33.8	133.2	(97.2-178.3)	Male	14	16.4	85.1	(46.5-142.8)
Female	14	12.6	111.1	(60.7-186.4)	Female	11	13.0	84.5	(42.1-151.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	6.0	133.1	(57.3-262.3)	Male	1	4.7	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)	Male	16	16.3	98.0	(56.0-159.2)
Female	112	127.8	87.7	(72.2-105.5)	Female	20	15.4	129.9	(79.3-200.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	5.6	nc	(nc-nc)	Male	14	12.4	113.1	(61.8-189.8)
Colon / Rectum					Female	8	6.2	128.4	(55.3-253.1)
Male	50	51.8	96.4	(71.6-127.1)	Ovary				
Female	52	51.1	101.8	(76.0-133.5)	Female	6	13.0	46.0	(16.8-100.1)
Esophagus					Pancreas				
Male	8	8.1	98.5	(42.4-194.1)	Male	11	9.6	114.3	(57.0-204.6)
Female	4	2.5	nc	(nc-nc)	Female	6	10.7	56.3	(20.6-122.6)
Hodgkin Lymphoma					Prostate				
Male	1	2.4	nc	(nc-nc)	Male	134	138.6	96.7	(81.0-114.5)
Female	1	2.1	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	12	13.1	91.5	(47.2-159.9)	Male	10	8.8	114.0	(54.6-209.7)
Female	8	8.9	90.0	(38.8-177.4)	Female	5	5.4	93.4	(30.1-218.0)
Larynx					Testis				
Male	8	6.0	133.3	(57.4-262.6)	Male	9	4.0	226.2	(103.2-429.4)
Female	1	1.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	15	9.9	151.4	(84.7-249.7)	Male	5	3.0	169.5	(54.6-395.5)
Female	9	8.3	108.0	(49.3-205.0)	Female	12	9.3	128.8	(66.5-224.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	10	6.1	164.9	(79.0-303.3)					
Female	3	2.4	nc	(nc-nc)	Female	34	25.6	132.9	(92.0-185.7)
Lung and Bronchus					All Sites / Types				
Male	72	66.4	108.4	(84.8-136.5)	Male	483	447.1	108.0	(98.6-118.1)
Female	66	58.6	112.6	(87.1-143.3)	Female	414	419.8	98.6	(89.3-108.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

273
Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)

Breast	Female	0	0.1	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Cervix Uteri	Female	2	2.7	nc	(nc-nc)
Colon / Rectum	Female	1	0.1	nc	(nc-nc)
	Male	0	1.2	nc	(nc-nc)
Esophagus	Female	0	0.9	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.0	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Larynx	Female	0	0.2	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Leukemia	Female	0	0.0	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.2	nc	(nc-nc)
	Male	2	0.2	nc	(nc-nc)
Lung and Bronchus	Female	0	0.0	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	0	0.1	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)
Oral Cavity & Pharynx	Female	0	0.3	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Ovary	Female	0	0.1	nc	(nc-nc)
Pancreas	Female	0	0.3	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Prostate	Female	0	0.2	nc	(nc-nc)
	Male	1	3.2	nc	(nc-nc)
Stomach	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Testis	Male	0	0.1	nc	(nc-nc)
Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	2	0.5	nc	(nc-nc)
All Sites / Types					

Male	1	1.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)

Male	7	10.5	66.7	(26.7-137.4)
Female	8	8.1	99.0	(42.6-195.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

274
Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	20.8	52.9	(26.4-94.6)	Male	20	10.5	189.9	(115.9-293.2)
Female	7	7.6	92.0	(36.8-189.5)	Female	9	8.3	108.4	(49.5-205.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	4.0	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.6	nc	(nc-nc)	Male	9	10.3	87.0	(39.7-165.1)
Female	78	81.6	95.6	(75.6-119.3)	Female	9	9.4	95.6	(43.6-181.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	3.7	nc	(nc-nc)	Male	11	8.2	134.5	(67.1-240.7)
Colon / Rectum					Female	7	3.9	179.6	(72.0-370.1)
Male	24	32.2	74.5	(47.7-110.9)	Ovary				
Female	29	30.6	94.7	(63.4-136.0)	Female	8	8.2	97.1	(41.8-191.3)
Esophagus					Pancreas				
Male	3	5.2	nc	(nc-nc)	Male	7	6.0	116.4	(46.6-239.8)
Female	2	1.5	nc	(nc-nc)	Female	7	6.4	109.8	(44.0-226.3)

Hodgkin Lymphoma					Prostate				
Male	1	1.5	nc	(nc-nc)	Male	82	89.0	92.1	(73.3-114.3)
Female	0	1.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	6	8.5	70.6	(25.8-153.7)	Male	3	5.4	nc	(nc-nc)
Female	1	5.5	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
Larynx					Testis				
Male	3	3.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	6.3	95.1	(34.7-207.0)	Male	1	1.9	nc	(nc-nc)
Female	8	5.2	153.1	(65.9-301.8)	Female	6	6.1	97.8	(35.7-212.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	3.9	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)	Female	18	16.2	110.9	(65.7-175.2)
Lung and Bronchus					All Sites / Types				
Male	45	41.6	108.1	(78.8-144.6)	Male	261	283.2	92.2	(81.3-104.0)
Female	36	35.6	101.0	(70.8-139.9)	Female	250	261.3	95.7	(84.2-108.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

275
Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	15.7	82.8	(44.0-141.5)	Male	7	8.1	86.4	(34.6-177.9)

Brain and Other Nervous System	Female	4	5.2	nc	(nc-nc)
	Male	5	3.0	164.7	(53.1-384.4)
Breast	Female	2	2.4	nc	(nc-nc)
	Male	1	0.5	nc	(nc-nc)
Cervix Uteri	Female	67	58.9	113.7	(88.1-144.5)
Colon / Rectum	Female	1	2.7	nc	(nc-nc)
	Male	19	24.4	78.0	(46.9-121.8)
Esophagus	Female	15	20.9	71.7	(40.1-118.3)
	Male	3	3.9	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	1.0	nc	(nc-nc)
	Male	1	1.2	nc	(nc-nc)
Kidney & Renal Pelvis	Female	2	1.0	nc	(nc-nc)
	Male	7	6.5	108.4	(43.4-223.4)
Larynx	Female	1	3.9	nc	(nc-nc)
	Male	2	2.9	nc	(nc-nc)
Leukemia	Female	0	0.7	nc	(nc-nc)
	Male	3	4.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	5	3.6	137.6	(44.4-321.2)

Multiple Myeloma	Female	7	6.1	114.9	(46.0-236.8)
	Male	2	2.2	nc	(nc-nc)
Non-Hodgkin Lymphoma	Female	2	1.6	nc	(nc-nc)
	Male	3	7.9	nc	(nc-nc)
Oral Cavity & Pharynx	Female	4	6.6	nc	(nc-nc)
	Male	5	6.3	79.9	(25.7-186.4)
Ovary	Female	2	2.8	nc	(nc-nc)
Pancreas	Female	6	5.9	101.6	(37.1-221.1)
	Male	3	4.6	nc	(nc-nc)
Prostate	Female	1	4.3	nc	(nc-nc)
	Male	61	66.5	91.7	(70.1-117.8)
Stomach	Male	12	4.1	292.8	(151.1-511.4)
	Female	0	2.2	nc	(nc-nc)
Testis	Male	3	2.0	nc	(nc-nc)
Thyroid	Male	1	1.5	nc	(nc-nc)
	Female	2	4.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	1	3.0	nc	(nc-nc)					
Female	2	1.0	nc	(nc-nc)	Female	9	11.6	77.8	(35.5-147.7)
Lung and Bronchus					All Sites / Types				
Male	25	31.3	79.7	(51.6-117.7)	Male	185	214.1	86.4	(74.4-99.8)
Female	13	24.9	52.3	(27.8-89.4)	Female	157	185.0	84.8	(72.1-99.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

276
Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	20	17.5	114.5	(69.9-176.8)	Male	11	9.5	115.7	(57.7-206.9)
Female	6	6.0	99.9	(36.5-217.5)	Female	13	7.4	175.7	(93.5-300.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.7	136.1	(43.9-317.7)	Male	4	2.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	16	9.2	173.6	(99.2-281.9)
Female	88	72.4	121.5	(97.4-149.7)	Female	13	7.7	168.4	(89.6-288.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.4	nc	(nc-nc)	Male	7	7.6	92.4	(37.0-190.4)
					Female	0	3.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	29	27.4	105.9	(70.9-152.1)					
Female	24	24.0	100.1	(64.1-148.9)	Female	7	7.2	97.6	(39.1-201.1)

Esophagus						Pancreas				
Male	1	4.5	nc	(nc-nc)		Male	8	5.2	154.7	(66.6-304.8)
Female	1	1.2	nc	(nc-nc)		Female	6	4.9	121.8	(44.5-265.1)
Hodgkin Lymphoma						Prostate				
Male	1	1.4	nc	(nc-nc)		Male	64	75.4	84.9	(65.4-108.4)
Female	3	1.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	7.6	nc	(nc-nc)		Male	7	4.7	150.4	(60.3-310.0)
Female	4	4.6	nc	(nc-nc)		Female	7	2.5	280.3	(112.3-577.6)
Larynx						Testis				
Male	1	3.4	nc	(nc-nc)		Male	4	2.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)						
Leukemia						Thyroid				
Male	5	5.6	89.1	(28.7-208.0)		Male	7	1.8	380.1	(152.3-783.2)
Female	2	4.4	nc	(nc-nc)		Female	13	5.8	222.8	(118.5-381.0)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	3	3.6	nc	(nc-nc)						
Female	0	1.2	nc	(nc-nc)		Female	13	14.1	92.4	(49.2-158.1)
Lung and Bronchus						All Sites / Types				
Male	31	35.0	88.5	(60.1-125.7)		Male	239	244.0	98.0	(85.9-111.2)
Female	26	28.6	91.1	(59.5-133.4)		Female	247	220.5	112.0	(98.5-126.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	4.3	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	9	15.3	58.8	(26.8-111.7)	Female	0	1.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
					Female	0	0.7	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	6	6.6	91.2	(33.3-198.5)					
Female	5	5.6	89.2	(28.7-208.1)	Female	0	1.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	1.0	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.3	nc	(nc-nc)	Male	21	17.9	117.5	(72.7-179.7)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Larynx					Testis				
Male	3	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				

Male	3	1.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.8	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	8	8.4	95.0	(40.9-187.2)	Male	59	57.2	103.1	(78.5-133.0)
Female	4	6.7	nc	(nc-nc)	Female	30	48.7	61.6	(41.5-87.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

278
Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	2.7	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	8	11.3	71.0	(30.6-139.9)	Female	1	1.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)

Colon / Rectum					Ovary				
Male	3	4.2	nc	(nc-nc)					
Female	10	5.0	198.9	(95.2-365.9)	Female	1	1.2	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	13	11.1	116.7	(62.1-199.6)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Larynx					Testis				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	0.8	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	5.3	nc	(nc-nc)	Male	41	36.0	113.8	(81.7-154.4)
Female	6	5.2	116.1	(42.4-252.6)	Female	49	38.1	128.7	(95.2-170.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Obs	Exp	SIR	95% CI	Obs	Exp	SIR	95% CI
-----	-----	-----	--------	-----	-----	-----	--------

Bladder, Urinary						Melanoma of Skin				
Male	5	4.6	108.5	(35.0-253.1)		Male	5	2.5	201.8	(65.0-470.9)
Female	0	1.4	nc	(nc-nc)		Female	4	1.8	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)		Male	0	2.4	nc	(nc-nc)
Female	20	18.3	109.5	(66.8-169.1)		Female	2	1.9	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	0	2.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	8	7.2	110.7	(47.6-218.1)						
Female	4	5.7	nc	(nc-nc)		Female	3	1.8	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	1.2	nc	(nc-nc)		Male	4	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)		Female	1	1.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.3	nc	(nc-nc)		Male	26	20.4	127.2	(83.1-186.4)
Female	0	0.3	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	1	2.0	nc	(nc-nc)		Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Larynx						Testis				

Male	0	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				
Male	4	1.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.9	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	9.4	nc	(nc-nc)	Male	63	64.7	97.4	(74.8-124.6)
Female	4	7.0	nc	(nc-nc)	Female	47	54.4	86.4	(63.5-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

280
Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	5.5	162.7	(74.2-308.8)	Male	3	3.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	23	21.4	107.6	(68.2-161.4)	Female	4	2.3	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx					
	Female	1	1.1	nc	(nc-nc)		Male	2	2.6	nc	(nc-nc)
Colon / Rectum							Female	1	1.0	nc	(nc-nc)
	Male	10	8.8	113.4	(54.3-208.6)	Ovary					
	Female	8	7.0	114.4	(49.3-225.4)		Female	3	2.1	nc	(nc-nc)
Esophagus						Pancreas					
	Male	5	1.5	340.1	(109.6-793.7)		Male	1	1.7	nc	(nc-nc)
	Female	1	0.3	nc	(nc-nc)		Female	0	1.4	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	1	0.8	nc	(nc-nc)		Male	20	24.2	82.6	(50.4-127.6)
	Female	0	0.4	nc	(nc-nc)	Stomach					
Kidney & Renal Pelvis							Male	1	1.5	nc	(nc-nc)
	Male	2	2.6	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
	Female	3	1.4	nc	(nc-nc)	Testis					
Larynx							Male	0	1.6	nc	(nc-nc)
	Male	2	1.1	nc	(nc-nc)	Thyroid					
	Female	1	0.2	nc	(nc-nc)		Male	2	0.8	nc	(nc-nc)
Leukemia							Female	3	2.0	nc	(nc-nc)
	Male	1	2.0	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	1	1.3	nc	(nc-nc)		Female	4	4.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						All Sites / Types					
	Male	2	1.2	nc	(nc-nc)		Male	89	81.6	109.0	(87.5-134.1)
	Female	0	0.3	nc	(nc-nc)		Female	79	65.8	120.0	(95.0-149.6)
Lung and Bronchus											
	Male	14	11.3	124.0	(67.7-208.1)						
	Female	14	8.5	164.3	(89.7-275.6)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

281 Shrewsbury									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	36	31.9	112.8	(79.0-156.1)	Male	12	16.7	71.7	(37.0-125.3)
Female	11	11.9	92.6	(46.2-165.7)	Female	8	13.6	59.0	(25.4-116.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	12	6.4	187.0	(96.5-326.6)	Male	2	4.5	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)	Male	20	16.4	122.0	(74.5-188.4)
Female	123	127.0	96.9	(80.5-115.6)	Female	16	15.0	106.8	(61.0-173.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	6.1	98.4	(35.9-214.2)	Male	7	12.5	56.0	(22.4-115.3)
					Female	4	6.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	38	49.4	76.9	(54.4-105.5)					
Female	47	48.3	97.4	(71.5-129.5)	Female	10	12.9	77.5	(37.1-142.5)
Esophagus					Pancreas				
Male	1	7.8	nc	(nc-nc)	Male	7	9.2	76.0	(30.5-156.6)
Female	1	2.4	nc	(nc-nc)	Female	11	10.0	109.9	(54.8-196.6)
Hodgkin Lymphoma					Prostate				
Male	2	2.8	nc	(nc-nc)	Male	113	130.8	86.4	(71.2-103.8)
Female	8	2.3	345.2	(148.6-680.3)					
Kidney & Renal Pelvis					Stomach				

Male	12	13.0	92.1	(47.6-161.0)
Female	9	8.6	104.5	(47.7-198.4)
Larynx				
Male	2	5.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Leukemia				
Male	6	10.1	59.5	(21.7-129.6)
Female	4	8.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	8	6.0	132.3	(56.9-260.6)
Female	1	2.3	nc	(nc-nc)
Lung and Bronchus				
Male	46	62.9	73.2	(53.6-97.6)
Female	44	55.2	79.7	(57.9-107.0)

Male	12	8.4	142.8	(73.7-249.4)
Female	3	5.1	nc	(nc-nc)
Testis				
Male	6	5.0	119.8	(43.7-260.7)
Thyroid				
Male	4	3.3	nc	(nc-nc)
Female	10	10.5	95.2	(45.6-175.0)
Uteri Corpus and Uterus, NOS				
Female	21	24.8	84.6	(52.3-129.3)
All Sites / Types				
Male	370	432.3	85.6	(77.1-94.8)
Female	370	410.7	90.1	(81.2-99.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

282 Shutesbury									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
	Male	0	0.0	nc	(nc-nc)		Male	1	0.8	nc (nc-nc)
	Female	9	6.5	138.2	(63.1-262.4)		Female	0	0.6	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.4	nc	(nc-nc)		Male	0	0.7	nc (nc-nc)
							Female	1	0.3	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	0	2.1	nc	(nc-nc)					
	Female	0	1.6	nc	(nc-nc)		Female	0	0.6	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.4	nc	(nc-nc)		Male	1	0.4	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.2	nc	(nc-nc)		Male	8	5.8	138.3 (59.5-272.4)
	Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.7	nc	(nc-nc)		Male	1	0.4	nc (nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Larynx						Testis				
	Male	0	0.3	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.5	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.7	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.3	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)		Female	2	1.2	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	2	2.7	nc	(nc-nc)		Male	17	19.7	86.2 (50.2-138.0)

Male	2	1.7	nc	(nc-nc)	Male	111	107.2	103.6	(85.2-124.7)
Female	1	1.5	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	10.0	80.0	(34.4-157.7)	Male	10	6.8	147.6	(70.7-271.5)
Female	10	7.0	142.0	(68.0-261.1)	Female	5	4.5	112.4	(36.2-262.2)
Larynx					Testis				
Male	4	4.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	10	7.5	132.5	(63.4-243.7)	Male	1	2.1	nc	(nc-nc)
Female	6	6.6	90.7	(33.1-197.5)	Female	7	6.5	107.8	(43.2-222.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	4.6	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)	Female	23	19.8	116.0	(73.5-174.1)
Lung and Bronchus					All Sites / Types				
Male	59	51.8	113.8	(86.6-146.8)	Male	364	344.5	105.7	(95.1-117.1)
Female	41	47.2	86.8	(62.3-117.8)	Female	319	331.5	96.2	(86.0-107.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

284
Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	56	58.2	96.3	(72.7-125.0)	Male	18	33.1	54.4	(32.2-86.0)
Female	19	25.4	74.7	(44.9-116.6)	Female	18	31.8	56.6	(33.5-89.4)

Brain and Other Nervous System						Multiple Myeloma				
Male	13	13.2	98.4	(52.4-168.3)		Male	8	8.1	98.2	(42.3-193.4)
Female	11	12.0	91.5	(45.6-163.7)		Female	5	7.9	63.1	(20.3-147.2)
Breast						Non-Hodgkin Lymphoma				
Male	1	1.8	nc	(nc-nc)		Male	31	32.4	95.7	(65.0-135.8)
Female	226	261.3	86.5	(75.6-98.5)		Female	31	32.9	94.1	(63.9-133.6)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	29	22.6	128.1	(85.8-183.9)
Female	15	14.2	105.5	(59.0-174.0)		Female	18	13.0	138.0	(81.8-218.1)
Colon / Rectum						Ovary				
Male	98	90.4	108.4	(88.0-132.2)						
Female	110	104.6	105.1	(86.4-126.7)		Female	19	27.4	69.4	(41.8-108.4)
Esophagus						Pancreas				
Male	21	14.0	149.9	(92.8-229.2)		Male	18	16.6	108.1	(64.0-170.9)
Female	2	5.1	nc	(nc-nc)		Female	16	21.7	73.8	(42.1-119.8)
Hodgkin Lymphoma						Prostate				
Male	4	8.2	nc	(nc-nc)		Male	201	231.8	86.7	(75.2-99.6)
Female	6	7.1	84.8	(31.0-184.7)						
Kidney & Renal Pelvis						Stomach				
Male	25	23.7	105.5	(68.3-155.7)		Male	15	15.5	96.7	(54.1-159.6)
Female	15	18.0	83.2	(46.5-137.3)		Female	16	11.3	141.7	(80.9-230.1)
Larynx						Testis				
Male	12	10.4	115.6	(59.6-201.9)		Male	27	16.9	159.7	(105.2-232.4)
Female	2	3.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	14	19.5	71.7	(39.2-120.3)		Male	5	7.6	65.5	(21.1-152.9)
Female	25	18.4	136.1	(88.1-201.0)		Female	34	26.9	126.5	(87.6-176.8)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	16	11.0	146.1	(83.4-237.2)						

Female	7	5.0	140.5	(56.3-289.5)	Female	44	50.5	87.2	(63.4-117.1)
Lung and Bronchus					All Sites / Types				
Male	135	113.3	119.2	(99.9-141.1)	Male	809	802.6	100.8	(94.0-108.0)
Female	129	115.4	111.8	(93.3-132.9)	Female	838	877.9	95.5	(89.1-102.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

285 South Hadley Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	22	20.8	105.8	(66.3-160.2)	Male	14	9.9	141.4	(77.2-237.3)
Female	9	8.3	108.7	(49.6-206.3)	Female	16	8.5	188.5	(107.7-306.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	3.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	5	3.5	144.6	(46.6-337.5)	Female	1	2.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.6	nc	(nc-nc)	Male	13	9.9	131.4	(69.9-224.6)
Female	92	80.3	114.6	(92.4-140.5)	Female	14	10.2	137.8	(75.3-231.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.5	nc	(nc-nc)	Male	8	7.3	108.9	(46.9-214.7)
Colon / Rectum					Female	5	4.0	124.8	(40.2-291.2)
Male	30	31.8	94.5	(63.7-134.9)	Ovary				
Female	30	34.1	88.0	(59.4-125.7)	Female	9	8.4	107.6	(49.1-204.2)
Esophagus					Pancreas				

Hodgkin Lymphoma	Male	6	4.9	122.9	(44.9-267.5)	Prostate	Male	8	5.9	136.2	(58.6-268.3)
	Female	0	1.7	nc	(nc-nc)		Female	9	7.1	126.7	(57.8-240.6)
Kidney & Renal Pelvis	Male	2	1.4	nc	(nc-nc)	Stomach	Male	73	82.5	88.5	(69.4-111.3)
	Female	1	1.7	nc	(nc-nc)		Female	6	5.4	111.2	(40.6-242.1)
Larynx	Male	7	7.9	89.1	(35.7-183.6)	Testis	Male	6	5.4	111.2	(40.6-242.1)
	Female	2	5.7	nc	(nc-nc)		Female	3	3.6	nc	(nc-nc)
Leukemia	Male	3	3.6	nc	(nc-nc)	Thyroid	Male	8	2.3	349.4	(150.4-688.5)
	Female	0	1.0	nc	(nc-nc)		Female	1	1.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	1	6.0	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	4	6.2	nc	(nc-nc)
	Female	5	5.6	89.1	(28.7-207.9)		Female	15	15.9	94.5	(52.8-155.8)
Lung and Bronchus	Male	2	3.7	nc	(nc-nc)	All Sites / Types	Male	268	270.0	99.3	(87.7-111.9)
	Female	0	1.6	nc	(nc-nc)		Female	272	271.6	100.1	(88.6-112.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin					
Male	1	5.0	nc	(nc-nc)		Male	3	2.8	nc	(nc-nc)	
Female	2	1.8	nc	(nc-nc)		Female	1	2.3	nc	(nc-nc)	
Brain and Other Nervous System						Multiple Myeloma					
Male	1	1.1	nc	(nc-nc)		Male	1	0.7	nc	(nc-nc)	
Female	0	0.9	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)	
Breast						Non-Hodgkin Lymphoma					
Male	0	0.2	nc	(nc-nc)		Male	3	2.7	nc	(nc-nc)	
Female	20	21.6	92.8	(56.6-143.3)		Female	0	2.3	nc	(nc-nc)	
Cervix Uteri						Oral Cavity & Pharynx					
Female	2	1.0	nc	(nc-nc)		Male	1	2.2	nc	(nc-nc)	
Colon / Rectum						Female	0	1.0	nc	(nc-nc)	
Male	6	7.9	75.9	(27.7-165.3)		Ovary					
Female	5	7.0	71.0	(22.9-165.6)		Female	2	2.1	nc	(nc-nc)	
Esophagus						Pancreas					
Male	0	1.3	nc	(nc-nc)		Male	3	1.5	nc	(nc-nc)	
Female	0	0.3	nc	(nc-nc)		Female	2	1.4	nc	(nc-nc)	
Hodgkin Lymphoma						Prostate					
Male	2	0.5	nc	(nc-nc)		Male	18	21.5	83.9	(49.7-132.6)	
Female	0	0.4	nc	(nc-nc)		Stomach					
Kidney & Renal Pelvis						Male	1	1.4	nc	(nc-nc)	
Male	0	2.2	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)	
Female	2	1.4	nc	(nc-nc)		Testis					
Larynx						Male	2	0.8	nc	(nc-nc)	
Male	0	1.0	nc	(nc-nc)		Thyroid					
Female	0	0.2	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)	
Leukemia											
Male	3	1.6	nc	(nc-nc)							

Female	1	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	9	10.0	89.9	(41.0-170.6)
Female	10	8.4	118.5	(56.7-217.9)

Female	2	1.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	4.2	nc	(nc-nc)
All Sites / Types				
Male	56	70.6	79.3	(59.9-103.0)
Female	62	65.6	94.5	(72.4-121.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

287

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	6.9	86.4	(31.5-188.0)
Female	1	2.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	49	30.0	163.3	(120.8-215.8)
Cervix Uteri				
Female	1	1.6	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	4.1	146.6	(53.5-319.1)
Female	2	3.3	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	3.9	153.1	(55.9-333.3)
Female	3	3.1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	3.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Ovary				

	Male	3	11.0	nc	(nc-nc)
	Female	9	9.1	98.7	(45.0-187.3)
Esophagus					
	Male	1	1.9	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	1	0.7	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	6	3.2	188.1	(68.7-409.4)
	Female	1	1.9	nc	(nc-nc)
Larynx					
	Male	0	1.4	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Leukemia					
	Male	2	2.4	nc	(nc-nc)
	Female	3	1.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					
	Male	2	1.5	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)
Lung and Bronchus					
	Male	8	14.1	56.8	(24.5-112.0)
	Female	4	11.1	nc	(nc-nc)

	Female	2	3.0	nc	(nc-nc)
Pancreas					
	Male	1	2.1	nc	(nc-nc)
	Female	0	1.9	nc	(nc-nc)
Prostate					
	Male	24	30.8	78.0	(50.0-116.1)
Stomach					
	Male	3	1.9	nc	(nc-nc)
	Female	2	0.9	nc	(nc-nc)
Testis					
	Male	1	1.3	nc	(nc-nc)
Thyroid					
	Male	0	0.9	nc	(nc-nc)
	Female	3	2.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	3	5.8	nc	(nc-nc)
All Sites / Types					
	Male	84	100.6	83.5	(66.6-103.4)
	Female	95	89.6	106.0	(85.8-129.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	21	18.7	112.4	(69.6-171.8)	Male	9	9.2	98.3	(44.9-186.7)
Female	2	7.9	nc	(nc-nc)	Female	3	7.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	3.5	200.4	(80.3-412.9)	Male	2	2.6	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	6	9.2	65.2	(23.8-142.0)
Female	62	73.9	83.9	(64.3-107.5)	Female	12	9.5	125.7	(64.9-219.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	3.3	179.6	(65.6-390.8)	Male	8	6.6	121.1	(52.2-238.7)
Colon / Rectum					Female	7	3.7	188.7	(75.6-388.9)
Male	28	28.5	98.1	(65.2-141.8)	Ovary				
Female	34	33.1	102.7	(71.1-143.6)	Female	13	7.7	168.0	(89.4-287.3)
Esophagus					Pancreas				
Male	0	4.3	nc	(nc-nc)	Male	9	5.3	170.5	(77.8-323.7)
Female	0	1.6	nc	(nc-nc)	Female	5	6.9	72.7	(23.4-169.6)
Hodgkin Lymphoma					Prostate				
Male	1	1.6	nc	(nc-nc)	Male	64	71.1	90.0	(69.3-115.0)
Female	0	1.4	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	4.9	nc	(nc-nc)
Male	7	7.0	99.6	(39.9-205.1)	Female	2	3.6	nc	(nc-nc)
Female	2	5.3	nc	(nc-nc)	Testis				
Larynx					Male	4	2.7	nc	(nc-nc)
Male	7	3.2	221.8	(88.9-457.1)					

Female	0	0.9	nc	(nc-nc)
Leukemia				
Male	4	5.7	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	3.3	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	41	35.5	115.5	(82.9-156.7)
Female	21	34.7	60.5	(37.5-92.5)

Thyroid

Male	2	1.7	nc	(nc-nc)
Female	5	5.7	88.2	(28.4-205.8)

Uteri Corpus and Uterus, NOS

Female	14	14.3	97.7	(53.4-164.0)
--------	----	------	------	--------------

All Sites / Types

Male	242	241.5	100.2	(88.0-113.7)
Female	215	253.9	84.7	(73.7-96.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

289 Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	8.3	144.3	(74.5-252.1)	Male	6	4.6	130.3	(47.6-283.7)
Female	5	2.9	174.3	(56.2-406.8)	Female	8	3.6	222.5	(95.8-438.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	5	4.5	111.5	(35.9-260.2)
Female	36	33.6	107.0	(74.9-148.2)	Female	6	3.7	160.5	(58.6-349.3)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	1	1.7	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
	Male	9	13.0	69.3	(31.6-131.5)	Female	0	1.6	nc	(nc-nc)
	Female	14	11.5	121.8	(66.6-204.4)	Ovary				
Esophagus	Male	2	2.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)	Pancreas				
	Male	2	2.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.6	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
	Male	1	0.8	nc	(nc-nc)	Prostate				
	Female	0	0.6	nc	(nc-nc)	Male	31	34.2	90.7	(61.6-128.7)
Kidney & Renal Pelvis	Male	2	3.5	nc	(nc-nc)	Stomach				
	Female	3	2.2	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
	Male	2	3.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Larynx	Female	0	0.4	nc	(nc-nc)	Testis				
	Male	1	1.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)	Thyroid				
Leukemia	Male	3	2.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
	Female	0	2.1	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
	Male	3	2.7	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts	Female	0	0.6	nc	(nc-nc)	Female	6	6.5	92.2	(33.7-200.6)
	Male	1	1.7	nc	(nc-nc)	All Sites / Types				
	Female	0	0.6	nc	(nc-nc)	Male	118	114.7	102.9	(85.2-123.2)
Lung and Bronchus	Male	27	16.4	164.9	(108.7-239.9)	Female	103	104.6	98.5	(80.4-119.5)
	Female	12	13.7	87.7	(45.2-153.2)					
	Male	27	16.4	164.9	(108.7-239.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

290
Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	12.2	49.2	(18.0-107.2)	Male	3	6.4	nc	(nc-nc)
Female	7	4.2	168.6	(67.6-347.5)	Female	4	4.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)	Male	6	6.3	95.6	(34.9-208.1)
Female	42	45.9	91.4	(65.9-123.6)	Female	8	5.3	150.4	(64.7-296.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	2.2	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Colon / Rectum					Female	4	2.2	nc	(nc-nc)
Male	16	18.9	84.6	(48.3-137.4)	Ovary				
Female	13	16.7	77.9	(41.4-133.2)	Female	6	4.7	128.7	(47.0-280.1)
Esophagus					Pancreas				
Male	1	3.0	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	1.1	nc	(nc-nc)	Male	27	50.7	53.2	(35.1-77.4)
Female	2	0.9	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	3.2	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)					

Larynx	Female	4	3.1	nc	(nc-nc)	Testis	Female	1	1.7	nc	(nc-nc)
	Male	1	2.3	nc	(nc-nc)		Male	3	1.9	nc	(nc-nc)
Leukemia	Female	0	0.6	nc	(nc-nc)	Thyroid					
	Male	1	3.8	nc	(nc-nc)		Male	3	1.3	nc	(nc-nc)
	Female	6	3.0	203.1	(74.2-442.1)		Female	7	3.9	179.7	(72.0-370.2)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	2	2.3	nc	(nc-nc)						
	Female	1	0.8	nc	(nc-nc)		Female	11	9.1	121.5	(60.6-217.4)
Lung and Bronchus						All Sites / Types					
	Male	19	24.1	78.8	(47.4-123.1)		Male	114	166.2	68.6	(56.6-82.4)
	Female	23	19.7	117.0	(74.1-175.5)		Female	160	146.6	109.2	(92.9-127.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

291 Springfield											
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002											
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI		
Bladder, Urinary					Melanoma of Skin						
Male	112	134.9	83.1	(68.4-99.9)	Male	40	68.3	58.6	(41.8-79.7)		
Female	43	55.6	77.3	(55.9-104.1)	Female	26	61.9	42.0	(27.4-61.5)		
Brain and Other Nervous System					Multiple Myeloma						
Male	22	27.5	80.1	(50.2-121.3)	Male	18	18.6	96.6	(57.2-152.7)		
Female	24	25.7	93.2	(59.7-138.7)	Female	15	17.4	86.4	(48.3-142.5)		
Breast					Non-Hodgkin Lymphoma						

Cervix Uteri	Male	2	4.0	nc	(nc-nc)
	Female	535	564.9	94.7	(86.9-103.1)
Colon / Rectum	Female	33	27.0	122.4	(84.2-171.9)
	Male	195	207.0	94.2	(81.4-108.4)
Esophagus	Female	230	228.0	100.9	(88.3-114.8)
	Male	45	31.8	141.3	(103.1-189.1)
Hodgkin Lymphoma	Female	10	11.1	89.7	(42.9-165.0)
	Male	8	12.9	62.0	(26.7-122.2)
Kidney & Renal Pelvis	Female	9	12.2	73.8	(33.7-140.0)
	Male	41	52.5	78.1	(56.0-105.9)
Larynx	Female	49	39.4	124.2	(91.9-164.2)
	Male	35	23.5	149.1	(103.8-207.3)
Leukemia	Female	5	6.9	72.3	(23.3-168.7)
	Male	32	43.4	73.8	(50.5-104.2)
Liver and Intrahepatic Bile Ducts	Female	32	40.1	79.7	(54.5-112.5)
	Male	27	24.4	110.6	(72.9-160.9)
Lung and Bronchus	Female	9	10.8	83.3	(38.0-158.1)
	Male	245	261.1	93.8	(82.5-106.4)
	Female	230	254.5	90.4	(79.1-102.8)

Oral Cavity & Pharynx	Male	69	68.5	100.8	(78.4-127.5)
	Female	58	69.9	83.0	(63.0-107.3)
Ovary	Male	58	49.5	117.2	(89.0-151.5)
	Female	17	27.8	61.2	(35.6-97.9)
Pancreas	Female	42	58.5	71.8	(51.7-97.0)
	Male	42	38.3	109.6	(79.0-148.2)
Prostate	Female	43	47.4	90.8	(65.7-122.3)
	Male	515	530.7	97.0	(88.8-105.8)
Stomach	Male	44	35.3	124.5	(90.4-167.1)
	Female	31	24.2	128.1	(87.0-181.8)
Testis	Male	25	22.5	111.0	(71.8-163.8)
	Male	5	13.3	37.6	(12.1-87.7)
Thyroid	Female	42	47.9	87.7	(63.2-118.6)
	Female	130	110.6	117.6	(98.2-139.6)
Uteri Corpus and Uterus, NOS					
All Sites / Types					
	Male	1702	1788.3	95.2	(90.7-99.8)
	Female	1749	1881.6	93.0	(88.6-97.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

292
Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	6.7	89.4	(32.6-194.6)	Male	2	3.9	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	6	3.7	162.8	(59.4-354.3)
Female	19	27.3	69.6	(41.9-108.7)	Female	4	2.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	1.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Colon / Rectum					Female	0	1.2	nc	(nc-nc)
Male	10	10.6	94.4	(45.2-173.6)	Ovary				
Female	3	8.3	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	1.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.6	nc	(nc-nc)	Male	35	28.9	121.3	(84.5-168.7)
Female	1	0.5	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
Male	2	3.0	nc	(nc-nc)		Male	1	1.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)		Female	1	0.9	nc	(nc-nc)
Larynx						Testis				
Male	1	1.3	nc	(nc-nc)		Male	3	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	2.2	nc	(nc-nc)		Male	0	0.8	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)		Female	0	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	1.4	nc	(nc-nc)						
Female	0	0.4	nc	(nc-nc)		Female	3	5.2	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	3	13.5	nc	(nc-nc)		Male	88	95.1	92.5	(74.2-114.0)
Female	9	10.1	89.5	(40.8-169.9)		Female	64	81.0	79.0	(60.8-100.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

293
Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	3.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)

Breast	Female	0	0.5	nc	(nc-nc)	Non-Hodgkin Lymphoma	Female	1	0.4	nc	(nc-nc)
	Male	2	0.1	nc	(nc-nc)		Male	2	1.8	nc	(nc-nc)
Cervix Uteri	Female	10	13.5	74.2	(35.5-136.4)	Oral Cavity & Pharynx	Female	0	1.6	nc	(nc-nc)
							Male	2	1.3	nc	(nc-nc)
Colon / Rectum	Female	0	0.6	nc	(nc-nc)	Ovary	Female	0	0.7	nc	(nc-nc)
	Male	3	5.9	nc	(nc-nc)						
Esophagus	Female	6	5.4	110.5	(40.4-240.6)	Pancreas	Female	1	1.4	nc	(nc-nc)
	Male	2	0.9	nc	(nc-nc)		Male	0	1.1	nc	(nc-nc)
Hodgkin Lymphoma	Female	2	0.3	nc	(nc-nc)	Prostate	Female	1	1.1	nc	(nc-nc)
	Male	1	0.2	nc	(nc-nc)		Male	9	15.1	59.8	(27.3-113.5)
Kidney & Renal Pelvis	Female	0	0.2	nc	(nc-nc)	Stomach					
	Male	0	1.4	nc	(nc-nc)		Male	1	1.0	nc	(nc-nc)
Larynx	Female	1	0.9	nc	(nc-nc)	Testis	Female	0	0.6	nc	(nc-nc)
	Male	2	0.7	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Leukemia	Female	0	0.2	nc	(nc-nc)	Thyroid					
	Male	0	1.1	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.8	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	1	0.9	nc	(nc-nc)
	Male	0	0.7	nc	(nc-nc)						
Lung and Bronchus	Female	0	0.3	nc	(nc-nc)	All Sites / Types	Female	1	2.7	nc	(nc-nc)

Male	4	7.5	nc	(nc-nc)	Male	37	49.2	75.1	(52.9-103.6)
Female	5	6.2	80.8	(26.0-188.5)	Female	34	44.0	77.2	(53.5-107.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

294
Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	31	28.2	110.1	(74.8-156.2)	Male	9	13.6	66.1	(30.2-125.5)
Female	12	11.4	105.5	(54.4-184.2)	Female	11	11.3	97.8	(48.7-175.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.0	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	5	4.6	109.9	(35.4-256.4)	Female	4	3.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)	Male	10	13.6	73.7	(35.3-135.6)
Female	133	108.9	122.1	(102.2-144.7)	Female	12	13.7	87.7	(45.3-153.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	4.8	104.4	(33.6-243.6)	Male	8	10.1	79.6	(34.3-156.8)
Colon / Rectum					Female	5	5.4	92.3	(29.7-215.4)
Male	56	43.1	130.0	(98.2-168.8)	Ovary				
Female	64	47.2	135.7	(104.5-173.3)	Female	13	11.3	115.4	(61.4-197.3)
Esophagus					Pancreas				
Male	8	6.6	120.8	(52.0-237.9)	Male	12	8.0	150.5	(77.7-262.9)
Female	2	2.3	nc	(nc-nc)	Female	19	9.8	192.9	(116.1-301.3)

Hodgkin Lymphoma					Prostate				
Male	6	2.0	293.6	(107.2-639.1)	Male	133	111.6	119.2	(99.8-141.2)
Female	1	1.8	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	12	10.7	112.3	(58.0-196.2)	Male	4	7.3	nc	(nc-nc)
Female	11	7.7	142.3	(71.0-254.7)	Female	8	5.1	157.5	(67.8-310.4)
Larynx					Testis				
Male	7	4.9	143.9	(57.6-296.4)	Male	3	3.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)					
Leukemia					Thyroid				
Male	11	8.3	133.0	(66.3-238.0)	Male	3	2.4	nc	(nc-nc)
Female	6	7.6	79.1	(28.9-172.1)	Female	7	7.9	88.7	(35.5-182.7)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	5.0	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)	Female	12	21.4	56.1	(29.0-98.0)
Lung and Bronchus					All Sites / Types				
Male	61	54.5	112.0	(85.6-143.8)	Male	406	367.0	110.6	(100.1-121.9)
Female	53	51.0	104.0	(77.9-136.0)	Female	406	368.2	110.3	(99.8-121.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

295
Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	34	30.6	111.1	(76.9-155.3)	Male	22	15.7	139.9	(87.7-211.8)

Female	5	11.9	41.9	(13.5-97.7)
Brain and Other Nervous System				
Male	4	5.9	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)
Breast				
Male	1	0.9	nc	(nc-nc)
Female	125	125.0	100.0	(83.2-119.1)
Cervix Uteri				
Female	9	5.7	157.6	(71.9-299.2)
Colon / Rectum				
Male	49	47.4	103.5	(76.6-136.8)
Female	42	48.2	87.0	(62.7-117.7)
Esophagus				
Male	7	7.5	92.8	(37.2-191.2)
Female	2	2.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	2.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	12.4	64.6	(27.8-127.2)
Female	11	8.5	128.8	(64.2-230.5)
Larynx				
Male	1	5.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Leukemia				
Male	7	9.4	74.5	(29.9-153.6)
Female	7	8.1	86.4	(34.6-177.9)
Liver and Intrahepatic Bile Ducts				

Female	18	13.1	137.7	(81.6-217.7)
Multiple Myeloma				
Male	2	4.3	nc	(nc-nc)
Female	10	3.7	267.7	(128.2-492.4)
Non-Hodgkin Lymphoma				
Male	17	15.5	109.9	(64.0-176.0)
Female	16	14.8	108.1	(61.7-175.5)
Oral Cavity & Pharynx				
Male	14	11.9	117.5	(64.2-197.1)
Female	7	6.0	115.7	(46.4-238.5)
Ovary				
Female	12	12.7	94.2	(48.6-164.5)
Pancreas				
Male	5	8.8	56.6	(18.3-132.2)
Female	13	10.0	129.5	(68.9-221.5)
Prostate				
Male	143	127.7	112.0	(94.4-131.9)
Stomach				
Male	7	8.0	87.3	(35.0-179.8)
Female	3	5.1	nc	(nc-nc)
Testis				
Male	4	4.4	nc	(nc-nc)
Thyroid				
Male	3	3.0	nc	(nc-nc)
Female	6	9.7	61.6	(22.5-134.0)
Uteri Corpus and Uterus, NOS				

Male	5	5.7	87.4	(28.2-203.9)					
Female	2	2.3	nc	(nc-nc)	Female	22	24.9	88.2	(55.3-133.6)
Lung and Bronchus					All Sites / Types				
Male	49	60.6	80.9	(59.8-107.0)	Male	409	414.6	98.6	(89.3-108.7)
Female	65	55.6	116.9	(90.2-148.9)	Female	412	406.2	101.4	(91.9-111.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

296
Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	4.8	nc	(nc-nc)	Male	7	2.9	240.3	(96.3-495.2)
Female	0	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	5	2.8	181.8	(58.6-424.2)
Female	19	22.1	85.8	(51.6-134.0)	Female	0	2.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
					Female	1	1.0	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	8	7.7	104.5	(45.0-205.9)					
Female	8	6.5	123.0	(53.0-242.4)	Female	0	2.2	nc	(nc-nc)

Esophagus						Pancreas				
Male	1	1.3	nc	(nc-nc)		Male	0	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)		Female	2	1.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.5	nc	(nc-nc)		Male	19	22.3	85.4	(51.4-133.3)
Female	0	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	2.3	nc	(nc-nc)		Male	0	1.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
Larynx						Testis				
Male	0	1.0	nc	(nc-nc)		Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	1.7	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)		Female	0	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	1.1	nc	(nc-nc)						
Female	0	0.3	nc	(nc-nc)		Female	3	4.3	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	6	9.9	60.9	(22.2-132.5)		Male	56	71.2	78.6	(59.4-102.1)
Female	5	8.0	62.8	(20.2-146.5)		Female	50	64.9	77.1	(57.2-101.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	9.0	133.7	(69.0-233.6)
Female	1	3.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	24	33.7	71.3	(45.6-106.0)
Cervix Uteri				
Female	1	1.6	nc	(nc-nc)
Colon / Rectum				
Male	12	13.9	86.3	(44.5-150.7)
Female	14	12.2	114.9	(62.8-192.8)
Esophagus				
Male	1	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	3.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)
Larynx				
Male	1	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	4.6	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	13	4.5	285.8	(152.0-488.8)
Female	5	3.9	129.7	(41.8-302.8)
Oral Cavity & Pharynx				
Male	4	3.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Ovary				
Female	5	3.4	147.3	(47.5-343.8)
Pancreas				
Male	2	2.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)
Prostate				
Male	33	37.4	88.2	(60.7-123.8)
Stomach				
Male	4	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Testis				
Male	0	1.2	nc	(nc-nc)
Thyroid				

Male	6	2.8	216.4	(79.0-470.9)	Male	1	0.9	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.7	nc	(nc-nc)					
Female	1	0.6	nc	(nc-nc)	Female	8	6.6	120.6	(51.9-237.6)
Lung and Bronchus					All Sites / Types				
Male	23	17.8	129.5	(82.1-194.3)	Male	128	121.8	105.1	(87.7-125.0)
Female	11	14.4	76.3	(38.0-136.5)	Female	88	106.8	82.4	(66.1-101.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

298 Sudbury Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	15	15.3	98.2	(54.9-161.9)	Male	12	8.7	138.5	(71.5-242.0)
Female	9	5.0	178.8	(81.6-339.4)	Female	15	6.7	223.8	(125.1-369.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.4	146.0	(47.1-340.8)	Male	1	2.2	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	12	8.3	144.4	(74.5-252.2)
Female	79	64.9	121.7	(96.4-151.7)	Female	4	6.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	3	7.0	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	18	24.2	74.4	(44.1-117.6)						
Female	22	19.7	111.4	(69.8-168.7)		Female	6	6.4	94.1	(34.4-204.9)
Esophagus						Pancreas				
Male	2	4.1	nc	(nc-nc)		Male	7	4.6	152.8	(61.2-314.8)
Female	2	1.0	nc	(nc-nc)		Female	6	4.0	148.4	(54.2-323.0)
Hodgkin Lymphoma						Prostate				
Male	0	1.4	nc	(nc-nc)		Male	72	69.5	103.6	(81.0-130.4)
Female	1	1.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	6.9	nc	(nc-nc)		Male	7	4.1	172.2	(69.0-354.9)
Female	1	4.0	nc	(nc-nc)		Female	2	2.1	nc	(nc-nc)
Larynx						Testis				
Male	3	3.1	nc	(nc-nc)		Male	4	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	5.1	nc	(nc-nc)		Male	1	1.8	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)		Female	7	5.5	127.7	(51.1-263.0)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	3.2	nc	(nc-nc)						
Female	0	1.0	nc	(nc-nc)		Female	6	12.7	47.1	(17.2-102.5)
Lung and Bronchus						All Sites / Types				
Male	22	31.3	70.3	(44.0-106.4)		Male	206	220.5	93.4	(81.1-107.1)
Female	25	24.3	102.7	(66.5-151.7)		Female	208	192.7	108.0	(93.8-123.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Obs	Exp	SIR	95% CI	Obs	Exp	SIR	95% CI
-----	-----	-----	--------	-----	-----	-----	--------

Bladder, Urinary						Melanoma of Skin				
Male	1	2.4	nc	(nc-nc)		Male	4	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)		Female	1	1.3	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	0	0.6	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)		Male	0	1.4	nc	(nc-nc)
Female	16	10.6	150.7	(86.1-244.7)		Female	1	1.3	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	1	3.7	nc	(nc-nc)						
Female	5	3.9	129.7	(41.8-302.6)		Female	1	1.1	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	0.6	nc	(nc-nc)		Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.4	nc	(nc-nc)		Male	11	9.5	116.1	(57.9-207.8)
Female	0	0.3	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	1.0	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)		Female	1	0.4	nc	(nc-nc)
Larynx						Testis				

Male	1	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	1	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	4.7	nc	(nc-nc)	Male	27	33.8	79.9	(52.7-116.3)
Female	3	4.2	nc	(nc-nc)	Female	37	34.4	107.7	(75.8-148.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

300
Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	6.9	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	5	3.1	162.1	(52.3-378.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	129.2	(41.6-301.4)
Female	18	28.0	64.2	(38.0-101.5)	Female	4	2.9	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx					
	Male	3	3.2	nc	(nc-nc)		Male	3	3.2	nc	(nc-nc)
	Female	0	1.3	nc	(nc-nc)		Female	0	1.3	nc	(nc-nc)
Colon / Rectum						Ovary					
	Male	12	11.0	109.5	(56.5-191.3)						
	Female	7	8.4	83.4	(33.4-171.8)						
Esophagus						Pancreas					
	Male	1	1.8	nc	(nc-nc)		Female	3	2.8	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Hodgkin Lymphoma							Female	2	1.7	nc	(nc-nc)
	Male	1	0.7	nc	(nc-nc)	Prostate					
	Female	2	0.6	nc	(nc-nc)		Male	24	29.8	80.5	(51.6-119.8)
Kidney & Renal Pelvis						Stomach					
	Male	6	3.1	191.8	(70.0-417.5)		Male	0	1.9	nc	(nc-nc)
	Female	3	1.7	nc	(nc-nc)		Female	0	0.9	nc	(nc-nc)
Larynx						Testis					
	Male	2	1.4	nc	(nc-nc)		Male	2	1.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)	Thyroid					
Leukemia							Male	0	0.8	nc	(nc-nc)
	Male	3	2.4	nc	(nc-nc)		Female	3	2.7	nc	(nc-nc)
	Female	3	1.7	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
Liver and Intrahepatic Bile Ducts							Female	7	5.4	130.0	(52.1-267.8)
	Male	1	1.5	nc	(nc-nc)	All Sites / Types					
	Female	0	0.4	nc	(nc-nc)		Male	87	98.7	88.1	(70.6-108.7)
Lung and Bronchus							Female	75	83.5	89.8	(70.6-112.6)
	Male	12	13.8	87.0	(44.9-152.0)						
	Female	8	10.4	77.3	(33.3-152.3)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

301

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	19	18.9	100.8	(60.6-157.4)	Male	23	9.0	254.2	(161.1-381.5)
Female	11	7.4	148.9	(74.2-266.4)	Female	10	7.5	133.9	(64.1-246.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	3.3	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	8	9.0	88.7	(38.2-174.8)
Female	83	73.2	113.5	(90.4-140.7)	Female	13	8.9	145.5	(77.4-248.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.2	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
					Female	4	3.6	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	20	28.8	69.3	(42.3-107.1)					
Female	26	30.8	84.4	(55.1-123.6)	Female	11	7.5	146.4	(73.0-262.0)
Esophagus					Pancreas				
Male	2	4.4	nc	(nc-nc)	Male	6	5.4	112.0	(40.9-243.7)
Female	1	1.5	nc	(nc-nc)	Female	8	6.4	125.1	(53.9-246.6)
Hodgkin Lymphoma					Prostate				
Male	1	1.3	nc	(nc-nc)	Male	80	72.9	109.7	(87.0-136.6)
Female	1	1.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	10	7.1	140.7	(67.3-258.7)	Testis	Male	1	5.0	nc	(nc-nc)
	Female	8	5.1	158.2	(68.1-311.8)		Female	4	3.3	nc	(nc-nc)
	Male	1	3.2	nc	(nc-nc)		Male	2	2.0	nc	(nc-nc)
	Female	0	0.9	nc	(nc-nc)						
Leukemia	Male	6	5.5	108.8	(39.7-236.7)	Thyroid	Male	4	1.6	nc	(nc-nc)
	Female	10	5.0	199.5	(95.5-366.9)		Female	6	5.3	113.5	(41.4-247.0)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	4	3.3	nc	(nc-nc)						
	Female	0	1.4	nc	(nc-nc)		Female	15	14.2	105.6	(59.1-174.2)
Lung and Bronchus						All Sites / Types					
	Male	25	35.9	69.7	(45.1-102.9)		Male	237	242.7	97.6	(85.6-110.9)
	Female	32	32.9	97.2	(66.5-137.2)		Female	279	243.0	114.8	(101.7-129.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

302
Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	17	19.5	87.1	(50.7-139.4)	Male	4	9.9	nc	(nc-nc)
Female	7	7.1	98.6	(39.5-203.1)	Female	5	7.6	65.4	(21.1-152.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.6	137.3	(44.2-320.4)	Male	2	2.7	nc	(nc-nc)
Female	6	3.0	197.8	(72.2-430.6)	Female	2	2.2	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma					
Male	0	0.6	nc	(nc-nc)		Male	10	9.7	102.8	(49.2-189.0)	
Female	52	74.7	69.6	(52.0-91.3)		Female	9	8.8	102.6	(46.8-194.7)	
Cervix Uteri						Oral Cavity & Pharynx					
						Male	3	7.5	nc	(nc-nc)	
Female	5	3.3	150.8	(48.6-351.8)		Female	1	3.6	nc	(nc-nc)	
Colon / Rectum						Ovary					
Male	32	30.2	106.1	(72.6-149.8)							
Female	23	28.7	80.2	(50.8-120.3)		Female	5	7.6	66.0	(21.3-153.9)	
Esophagus						Pancreas					
Male	3	4.8	nc	(nc-nc)		Male	4	5.6	nc	(nc-nc)	
Female	2	1.4	nc	(nc-nc)		Female	7	6.0	117.3	(47.0-241.7)	
Hodgkin Lymphoma						Prostate					
Male	1	1.5	nc	(nc-nc)		Male	90	80.3	112.1	(90.1-137.8)	
Female	2	1.2	nc	(nc-nc)							
Kidney & Renal Pelvis						Stomach					
Male	7	7.8	89.7	(35.9-184.8)		Male	4	5.1	nc	(nc-nc)	
Female	3	5.1	nc	(nc-nc)		Female	2	3.0	nc	(nc-nc)	
Larynx						Testis					
Male	2	3.6	nc	(nc-nc)		Male	0	2.5	nc	(nc-nc)	
Female	1	0.9	nc	(nc-nc)							
Leukemia						Thyroid					
Male	7	5.9	119.1	(47.7-245.3)		Male	1	1.8	nc	(nc-nc)	
Female	2	4.7	nc	(nc-nc)		Female	4	5.6	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	5	3.6	137.8	(44.4-321.5)							
Female	1	1.4	nc	(nc-nc)		Female	12	14.9	80.8	(41.7-141.1)	
Lung and Bronchus						All Sites / Types					
Male	52	38.4	135.4	(101.1-177.6)		Male	260	261.5	99.4	(87.7-112.3)	

Female 27 33.2 81.3 (53.5-118.2)

Female 188 241.3 77.9 (67.2-89.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

303
Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	75	53.3	140.7	(110.6-176.3)	Male	11	27.9	39.5	(19.7-70.6)
Female	35	21.3	164.3	(114.4-228.5)	Female	20	24.0	83.4	(50.9-128.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	11	10.9	101.2	(50.5-181.2)	Male	5	7.5	67.0	(21.6-156.4)
Female	8	9.7	82.6	(35.6-162.7)	Female	7	6.6	105.3	(42.2-216.9)
Breast					Non-Hodgkin Lymphoma				
Male	2	1.6	nc	(nc-nc)	Male	27	27.5	98.3	(64.8-143.1)
Female	233	219.7	106.0	(92.9-120.6)	Female	29	26.8	108.4	(72.5-155.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	10.6	56.6	(20.7-123.2)	Male	30	20.5	146.0	(98.5-208.5)
					Female	11	10.7	102.6	(51.2-183.6)
Colon / Rectum					Ovary				
Male	84	82.4	101.9	(81.3-126.2)					
Female	92	87.3	105.4	(85.0-129.2)	Female	14	22.6	61.9	(33.8-103.8)
Esophagus					Pancreas				
Male	16	13.0	123.5	(70.5-200.5)	Male	16	15.3	104.4	(59.6-169.6)
Female	5	4.3	117.3	(37.8-273.8)	Female	21	18.1	116.0	(71.8-177.4)
Hodgkin Lymphoma					Prostate				

Male	4	5.0	nc	(nc-nc)	Male	210	217.3	96.6	(84.0-110.6)
Female	1	4.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	26	21.5	120.9	(78.9-177.1)	Male	29	14.0	206.9	(138.5-297.1)
Female	23	15.1	152.0	(96.3-228.0)	Female	11	9.3	118.6	(59.1-212.2)
Larynx					Testis				
Male	18	9.6	186.5	(110.5-294.8)	Male	10	9.1	110.2	(52.7-202.6)
Female	6	2.7	223.8	(81.7-487.1)					
Leukemia					Thyroid				
Male	18	17.0	106.2	(62.9-167.8)	Male	2	5.5	nc	(nc-nc)
Female	19	15.1	125.4	(75.5-195.9)	Female	20	18.6	107.6	(65.7-166.2)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	9	10.0	90.4	(41.2-171.6)					
Female	3	4.1	nc	(nc-nc)	Female	42	43.0	97.7	(70.4-132.0)
Lung and Bronchus					All Sites / Types				
Male	148	104.6	141.4	(119.6-166.1)	Male	808	720.9	112.1	(104.5-120.1)
Female	101	97.6	103.5	(84.3-125.7)	Female	750	725.1	103.4	(96.2-111.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

304
Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	7.4	67.7	(21.8-157.9)	Male	6	3.9	152.1	(55.6-331.2)
Female	1	2.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)

Brain and Other Nervous System						Multiple Myeloma				
Male	1	1.5	nc	(nc-nc)		Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)		Male	4	3.8	nc	(nc-nc)
Female	21	27.4	76.7	(47.5-117.2)		Female	4	3.2	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	1	3.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)		Female	1	1.3	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	14	11.5	121.6	(66.4-204.1)						
Female	9	10.3	87.4	(39.9-165.9)		Female	5	2.8	179.9	(58.0-419.9)
Esophagus						Pancreas				
Male	3	1.9	nc	(nc-nc)		Male	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	3	2.1	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.6	nc	(nc-nc)		Male	33	31.2	105.6	(72.7-148.3)
Female	1	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	1	3.1	nc	(nc-nc)		Male	2	2.0	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)		Female	1	1.1	nc	(nc-nc)
Larynx						Testis				
Male	0	1.4	nc	(nc-nc)		Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)						
Leukemia						Thyroid				
Male	3	2.3	nc	(nc-nc)		Male	1	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)		Female	2	2.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	1.4	nc	(nc-nc)						

Female	1	0.5	nc	(nc-nc)	Female	9	5.3	168.7	(77.0-320.3)
Lung and Bronchus					All Sites / Types				
Male	21	14.7	142.6	(88.2-218.0)	Male	104	101.7	102.2	(83.5-123.9)
Female	16	11.8	135.5	(77.4-220.1)	Female	87	88.1	98.8	(79.1-121.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

<div>305</div> <div>Tewksbury</div> <div>Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002</div>									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	27	27.4	98.5	(64.9-143.3)	Male	16	15.2	105.6	(60.3-171.5)
Female	10	9.8	101.8	(48.7-187.2)	Female	15	12.3	122.1	(68.3-201.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	6.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	6	4.9	123.7	(45.2-269.2)	Female	3	3.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)	Male	16	14.7	108.8	(62.2-176.7)
Female	109	114.5	95.2	(78.2-114.9)	Female	14	12.7	110.2	(60.2-184.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	7	5.6	124.3	(49.8-256.0)	Male	11	11.7	94.3	(47.0-168.7)
					Female	7	5.4	130.5	(52.3-269.0)
Colon / Rectum					Ovary				
Male	41	43.0	95.4	(68.5-129.5)					
Female	60	38.9	154.4	(117.8-198.7)	Female	12	11.5	104.6	(54.0-182.7)
Esophagus					Pancreas				

Male	5	7.1	70.9	(22.8-165.4)
Female	1	1.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	5	2.7	187.6	(60.5-437.8)
Female	4	2.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	14	11.9	118.1	(64.5-198.2)
Female	6	7.5	80.1	(29.3-174.4)
Larynx				
Male	3	5.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Leukemia				
Male	8	8.9	89.7	(38.6-176.8)
Female	7	7.1	98.7	(39.5-203.4)
Liver and Intrahepatic Bile Ducts				
Male	11	5.5	200.9	(100.1-359.5)
Female	0	1.9	nc	(nc-nc)
Lung and Bronchus				
Male	80	55.2	145.0	(115.0-180.5)
Female	53	47.2	112.3	(84.1-146.9)

Male	7	8.1	86.8	(34.8-178.8)
Female	4	8.0	nc	(nc-nc)
Prostate				
Male	121	119.9	101.0	(83.8-120.6)
Stomach				
Male	3	7.3	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)
Testis				
Male	8	4.8	166.0	(71.5-327.1)
Thyroid				
Male	4	3.1	nc	(nc-nc)
Female	6	9.9	60.4	(22.1-131.4)
Uteri Corpus and Uterus, NOS				
Female	18	22.7	79.3	(47.0-125.3)
All Sites / Types				
Male	401	386.8	103.7	(93.8-114.3)
Female	367	356.7	102.9	(92.6-114.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	3	4.4	nc	(nc-nc)		Male	6	2.2	274.8	(100.3-598.1)
Female	2	2.0	nc	(nc-nc)		Female	2	1.9	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	0	0.8	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)		Male	1	2.2	nc	(nc-nc)
Female	20	19.3	103.8	(63.4-160.3)		Female	0	2.4	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	0.8	nc	(nc-nc)		Male	1	1.6	nc	(nc-nc)
Colon / Rectum						Female	4	0.9	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)		Ovary				
Female	4	8.3	nc	(nc-nc)		Female	2	2.0	nc	(nc-nc)
Esophagus						Pancreas				
Male	0	1.0	nc	(nc-nc)		Male	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)		Female	2	1.7	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.3	nc	(nc-nc)		Male	26	17.3	150.7	(98.4-220.8)
Female	0	0.3	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	2	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)		Female	1	0.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)		Testis				
Larynx						Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)		Thyroid				
Female	1	0.2	nc	(nc-nc)		Male	1	0.4	nc	(nc-nc)
Leukemia										
Male	2	1.3	nc	(nc-nc)						

Female	1	1.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	0.8	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	11	8.5	128.9	(64.2-230.6)	Male	69	57.6	119.7	(93.1-151.5)
Female	10	8.9	112.0	(53.6-206.0)	Female	63	64.5	97.6	(75.0-124.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

307
Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				

Esophagus	Male	0	0.9	nc	(nc-nc)	Pancreas	Female	0	0.1	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)						
Hodgkin Lymphoma	Male	0	0.1	nc	(nc-nc)	Prostate	Male	1	0.2	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis	Male	1	0.0	nc	(nc-nc)	Stomach	Male	1	2.6	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.0	nc	(nc-nc)
Larynx	Male	0	0.2	nc	(nc-nc)	Testis	Male	0	0.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.0	nc	(nc-nc)
Leukemia	Male	0	0.1	nc	(nc-nc)	Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.2	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Lung and Bronchus	Male	0	0.1	nc	(nc-nc)	All Sites / Types	Male	5	7.8	63.9	(20.6-149.1)
	Female	0	0.0	nc	(nc-nc)		Female	2	4.5	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

308
Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	8.0	nc	(nc-nc)	Male	7	3.9	178.0	(71.3-366.7)
Female	3	2.8	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	23	29.3	78.5	(49.7-117.8)	Female	5	3.4	147.6	(47.6-344.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	1.3	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Colon / Rectum					Female	0	1.4	nc	(nc-nc)
Male	8	12.3	65.2	(28.1-128.6)	Ovary				
Female	18	11.2	160.3	(94.9-253.3)	Female	6	3.0	202.5	(74.0-440.8)
Esophagus					Pancreas				
Male	1	1.9	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.5	nc	(nc-nc)	Male	37	32.8	112.6	(79.3-155.3)
Female	0	0.4	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	2.1	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Testis				
Larynx					Male	1	0.8	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)					

Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	4	2.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	13	15.6	83.1	(44.2-142.1)
Female	8	12.8	62.7	(27.0-123.5)

Thyroid

Male	0	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	7	5.8	121.2	(48.6-249.8)
--------	---	-----	-------	--------------

All Sites / Types

Male	88	105.9	83.1	(66.6-102.3)
Female	95	94.1	101.0	(81.7-123.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

309

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	5.9	152.8	(69.7-290.2)	Male	2	3.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	30	30.0	100.2	(67.6-143.0)	Female	2	3.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	1	1.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
	Male	8	9.5	84.2	(36.3-166.0)	Female	2	1.3	nc	(nc-nc)
	Female	6	8.6	69.5	(25.4-151.2)	Ovary				
Esophagus	Male	2	1.6	nc	(nc-nc)		Female	6	2.9	204.3 (74.6-444.7)
	Female	0	0.4	nc	(nc-nc)					
	Male	2	1.6	nc	(nc-nc)	Pancreas	Male	2	1.8	nc (nc-nc)
Hodgkin Lymphoma	Female	0	0.4	nc	(nc-nc)		Female	1	1.7	nc (nc-nc)
	Male	0	0.8	nc	(nc-nc)					
	Female	1	0.7	nc	(nc-nc)	Prostate	Male	40	25.6	156.1 (111.5-212.6)
Kidney & Renal Pelvis	Male	7	2.9	240.0	(96.2-494.5)					
	Female	0	1.8	nc	(nc-nc)		Male	2	1.6	nc (nc-nc)
	Male	1	1.3	nc	(nc-nc)	Stomach	Female	1	0.9	nc (nc-nc)
Larynx	Female	0	0.3	nc	(nc-nc)					
	Male	1	1.3	nc	(nc-nc)		Male	1	1.5	nc (nc-nc)
	Female	0	0.3	nc	(nc-nc)	Thyroid	Male	1	0.9	nc (nc-nc)
Leukemia	Male	2	2.2	nc	(nc-nc)		Female	4	3.0	nc (nc-nc)
	Female	0	1.8	nc	(nc-nc)					
	Male	2	2.2	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts	Female	0	1.8	nc	(nc-nc)		Female	7	5.5	127.5 (51.1-262.6)
	Male	1	1.4	nc	(nc-nc)					
	Female	0	0.4	nc	(nc-nc)	All Sites / Types	Male	95	88.1	107.9 (87.3-131.9)
Lung and Bronchus	Male	10	11.9	84.0	(40.2-154.5)		Female	83	87.8	94.5 (75.3-117.2)
	Female	8	10.4	76.8	(33.1-151.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

310

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	3.2	157.8	(50.9-368.3)	Male	0	1.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	1.1	555.0	(202.7-1208.0)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	16	11.0	146.0	(83.4-237.1)	Female	1	1.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.5	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
					Female	0	0.5	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	4	4.9	nc	(nc-nc)					
Female	3	4.0	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	17	12.8	132.8	(77.3-212.6)
Female	1	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)

Larynx	Female	0	0.7	nc	(nc-nc)	Testis	Female	0	0.4	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Thyroid					
	Male	2	0.9	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
	Female	1	0.7	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.6	nc	(nc-nc)						
	Female	0	0.2	nc	(nc-nc)		Female	5	2.2	226.2	(72.9-528.0)
Lung and Bronchus						All Sites / Types					
	Male	7	6.2	113.5	(45.5-233.8)		Male	51	41.3	123.6	(92.0-162.5)
	Female	5	4.8	104.2	(33.6-243.3)		Female	46	34.6	133.1	(97.4-177.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

311

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	6.9	173.0	(89.3-302.3)	Male	1	4.5	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	6	1.9	318.6	(116.3-693.4)	Male	1	1.0	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Cervix Uteri	Male	1	0.2	nc	(nc-nc)
	Female	24	33.7	71.3	(45.7-106.1)
Colon / Rectum	Female	1	1.9	nc	(nc-nc)
	Male	9	11.1	81.0	(37.0-153.9)
Esophagus	Female	14	9.8	142.5	(77.8-239.1)
	Male	2	1.9	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.5	nc	(nc-nc)
	Male	0	0.9	nc	(nc-nc)
Kidney & Renal Pelvis	Female	2	0.8	nc	(nc-nc)
	Male	2	3.4	nc	(nc-nc)
Larynx	Female	2	2.0	nc	(nc-nc)
	Male	2	1.4	nc	(nc-nc)
Leukemia	Female	0	0.4	nc	(nc-nc)
	Male	2	2.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	5	2.1	241.0	(77.7-562.5)
	Male	3	1.6	nc	(nc-nc)
Lung and Bronchus	Female	0	0.5	nc	(nc-nc)
	Male	15	14.1	106.7	(59.7-176.1)
	Female	11	12.1	91.2	(45.5-163.2)

Oral Cavity & Pharynx	Male	4	4.2	nc	(nc-nc)
	Female	7	3.5	199.8	(80.0-411.7)
Ovary	Male	7	3.4	205.1	(82.2-422.5)
	Female	0	1.5	nc	(nc-nc)
Pancreas	Female	3	3.3	nc	(nc-nc)
	Male	1	2.1	nc	(nc-nc)
Prostate	Female	2	2.0	nc	(nc-nc)
	Male	34	30.3	112.3	(77.8-157.0)
Stomach	Male	2	1.9	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)
Testis	Male	2	1.8	nc	(nc-nc)
	Male	2	1.0	nc	(nc-nc)
Thyroid	Female	2	3.5	nc	(nc-nc)
	Male	2	1.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	4	6.3	nc	(nc-nc)
	Male	115	103.1	111.6	(92.1-133.9)
All Sites / Types	Female	88	100.1	87.9	(70.5-108.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

312
Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Colon / Rectum					Female	0	0.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Ovary				
Female	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Larynx						Testis					
	Male	0	0.1	nc	(nc-nc)		Male	0	0.0	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.1	nc	(nc-nc)						
	Female	0	0.0	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	0	1.2	nc	(nc-nc)		Male	4	8.6	nc	(nc-nc)
	Female	0	0.8	nc	(nc-nc)		Female	1	6.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

313
Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	4.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)

Breast	Female	2	0.9	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Cervix Uteri	Female	23	20.3	113.3	(71.8-170.0)
	Male	0	1.1	nc	(nc-nc)
Colon / Rectum	Female	9	7.2	125.3	(57.2-237.8)
	Male	9	7.1	127.0	(58.0-241.2)
Esophagus	Female	1	1.2	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.5	nc	(nc-nc)
	Male	1	0.4	nc	(nc-nc)
Kidney & Renal Pelvis	Female	3	2.0	nc	(nc-nc)
	Male	1	1.3	nc	(nc-nc)
Larynx	Female	0	0.9	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Leukemia	Female	2	1.6	nc	(nc-nc)
	Male	1	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	1.0	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Lung and Bronchus	Female	0	0.3	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	1	0.5	nc	(nc-nc)
	Male	1	2.5	nc	(nc-nc)
Oral Cavity & Pharynx	Female	2	2.3	nc	(nc-nc)
	Male	2	2.1	nc	(nc-nc)
Ovary	Female	1	0.9	nc	(nc-nc)
	Male	3	2.0	nc	(nc-nc)
Pancreas	Female	1	1.4	nc	(nc-nc)
	Male	1	1.5	nc	(nc-nc)
Prostate	Female	20	19.5	102.7	(62.7-158.7)
	Male	20	19.5	102.7	(62.7-158.7)
Stomach	Female	1	1.2	nc	(nc-nc)
	Male	1	0.7	nc	(nc-nc)
Testis	Female	2	0.9	nc	(nc-nc)
	Male	2	0.9	nc	(nc-nc)
Thyroid	Female	0	0.6	nc	(nc-nc)
	Male	1	1.9	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	4	3.8	nc	(nc-nc)
	Male	4	3.8	nc	(nc-nc)
All Sites / Types	Female	4	3.8	nc	(nc-nc)
	Male	4	3.8	nc	(nc-nc)

Male	9	9.1	99.1	(45.2-188.1)
Female	8	8.1	99.0	(42.6-195.1)

Male	59	64.8	91.1	(69.3-117.5)
Female	67	63.5	105.5	(81.7-133.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

314
Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	9.4	170.5	(97.4-276.9)	Male	3	5.3	nc	(nc-nc)
Female	5	3.7	136.3	(43.9-318.0)	Female	1	4.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	9	5.1	175.2	(79.9-332.5)
Female	44	41.0	107.4	(78.0-144.1)	Female	3	4.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	2.1	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Colon / Rectum					Female	2	1.9	nc	(nc-nc)
Male	13	14.7	88.6	(47.2-151.6)	Ovary				
Female	18	14.9	121.0	(71.7-191.2)	Female	3	4.2	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	2.4	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)

Hodgkin Lymphoma						Prostate				
Male	1	1.0	nc	(nc-nc)		Male	41	39.2	104.6	(75.1-141.9)
Female	1	0.9	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	4.0	nc	(nc-nc)		Male	2	2.5	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)		Female	2	1.6	nc	(nc-nc)
Larynx						Testis				
Male	1	1.8	nc	(nc-nc)		Male	3	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	3.2	nc	(nc-nc)		Male	0	1.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)		Female	1	3.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	1.9	nc	(nc-nc)						
Female	1	0.7	nc	(nc-nc)		Female	12	7.8	153.0	(79.0-267.4)
Lung and Bronchus						All Sites / Types				
Male	27	18.6	145.0	(95.5-210.9)		Male	146	131.1	111.4	(94.0-131.0)
Female	17	17.0	99.8	(58.1-159.8)		Female	134	130.9	102.4	(85.8-121.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;